Recently, Jiangsu Pacific Meinuoke Biopharmaceutical Co, Ltd. was approved to establish the Jiangsu Antibody Drug Engineering Center.

Pacific Meinuoke and the Research Center for Cell Engineering of the No.4 Military Medical University will make joint efforts to build this center. A total of RMB 10 million will be invested on the construction of the technological laboratory and the pilot production plant of mammalian cell culture with a capacity of 5L-300L.

After completion, this antibody drug engineering center will become a one-stop R&D service platform, which will make breakthroughs in the development of modern biotechnology industry, and thus speed up the industrialization process of China-made antibody therapeutics.

扫一扫在手机打开当前页